沙利文发布《2026全球干细胞行业发展蓝皮书》
Frost & Sullivan Releases the " 2026 Global Stem Cell Industry Development Blue Book "
干细胞疗法基于干细胞自我更新与多向分化的独特生物学特性，通过体外制备及移植干预，实现受损细胞、组织或器官的修复与再生，是当代最具前景的细胞治疗手段之一。当前，全球退行性疾病、自身免疫病及脏器损伤等临床需求持续攀升，各国监管框架渐趋成熟，iPSC重编程、基因编辑、标准化细胞生产、类器官建模等前沿技术加速落地，推动干细胞行业从基础科研探索大步迈向标准化临床转化与产业化发展的关键阶段。
在此背景下，弗若斯特沙利文（简称"沙利文"）撰写了《2026全球干细胞行业发展蓝皮书》（以下简称"蓝皮书"）。蓝皮书旨在对全球干细胞行业进行深入分析，从干细胞基础定义与分类、干细胞多疾病临床应用场景、全球主要国家干细胞监管政策体系、干细胞疗法核心技术现状、临床转化现存挑战及未来行业发展趋势等多维度进行全面阐述，梳理行业与技术发展脉络，挖掘产业发展潜力，剖析市场发展背后的技术、临床、政策驱动因素。
Stem cell therapy, leveraging the unique biological properties of self-renewal and multilineage differentiation, enables the repair and regeneration of damaged cells, tissues, or organs through in vitro preparation and transplantation intervention, making it one of the most promising cell-based therapeutic modalities today. Currently, with the rising global clinical demand for degenerative diseases, autoimmune disorders, and organ injuries, and as regulatory frameworks in various countries continue to mature, cutting-edge technologies such as iPSC reprogramming, gene editing, standardized cell manufacturing, and organoid modeling are being rapidly deployed. These advances are propelling the stem cell industry into a critical transition period—from basic scientific exploration toward standardized clinical translation and industrial-scale commercialization.
Against this backdrop, Frost & Sullivan has prepared the 2026 Global Stem Cell Industry Development Blue Book, which provides an in-depth analysis of the global stem cell industry, offering a comprehensive overview across multiple dimensions—including the fundamental definition and classification of stem cells, clinical application scenarios across various disease areas, regulatory policy frameworks in major countries worldwide, the current state of core stem cell technologies, existing challenges in clinical translation, and future industry trends. It seeks to map out the technological and industrial evolution, identify growth opportunities, and dissect the technological, clinical, and policy drivers underpinning market development.
